Overview
Legal name
IXAKA LIMITED
Region
South West England
Registered address
Unknown
Insolvency history
No
Company
Active
LTD
Company profile
IXAKA Limited
Ixaka innovative cell therapies
IXAKA Limited is a UK company with status active founded in 2015 based in South West England.
CRN
09427131
Founded
2015
Age
11
Company events
Reference milestones and recent Companies House filing stream events.
2 events
04 Sep
2024
Liquidation In Administration Progress Report
InsolvencyAM10 | Transaction MzQzMzk1MDI4N2FkaXF6a2N4 | Paper/PDF filed
Published 05 Sep 2024 06:35
06 Feb
2015
Incorporated
InceptionCompany registered at Companies House
Public funding
3 awards
First funded
2018
Funded years
2018, 2021
Age at first award
3 years
Projects
2021
Centres
MW-ATTC - Runway
1 Apr 2021 to 31 Mar 2022
Awarded
£0
Total cost £0
2018
Collaborative R&D
Lead participant
Cost-driven process redesign, automation and scale-out for commercial manufacture of REX-001 therapy
1 Mar 2018 to 31 Mar 2021
Awarded
£397,508
Total cost £567,868
"Rexgenero's lead program (REX-001) is an innovative autologous cell therapy in late-stage development for critical limb ischaemia, a major disease with high unmet medical need. REX-001 is in the last phase of clinical development, but making this potential new treatment available to the many patients who need it is currently limited by the ability to man...
2018
Collaborative R&D
Midlands & Wales Advanced Therapy Treatment Centre (MW-ATTC)
1 Mar 2018 to 31 Mar 2022
Awarded
£332,414
Total cost £474,877
"ATMPs, which can be _cell or gene therapies_, show great potential in treating patients with conditions that cannot be cured with current treatments. These include arthritis, liver disease, several types of cancer, and diabetic ulcers. ATMPs are just beginning to be available, with the UK playing a leading role. However, even when new ATMP therapies are ...
Product types
Centres
Collaborative R&D